Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 559-572

  Fang, Ying ^a   Fu, Da ^a   Tang, Wenqing ^a   Cai, Yu ^a   Ma, Duan ^a   Wang, Huijun ^a   Xue, Ruyi ^a   Liu, Taotao ^a   Huang, Xiaowu ^a   Dong, Ling ^a   Wu, Hao ^a   Shen, Xizhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

HCC; Invasion; Migration; PRP19; UCH37

Indexed keywords

CELL PROTEIN; PRE MRNA PROCESSING FACTOR 19; UBIQUITIN C TERMINAL HYDROLASE 37; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ADULT; ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; CELL CYCLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA SPLICING; UBIQUITINATION;

APOPTOSIS; BLOTTING, WESTERN; CARBOXYPEPTIDASES; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DNA REPAIR ENZYMES; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; UBIQUITIN; WOUND HEALING;

EID: 84871887523     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.11.020     Document Type: Article

References (57)

1. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
2. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
3. Tang Z.Y., Ye S.L., Liu Y.K., Qin L.X., Sun H.C., Ye Q.H., Wang L., Zhou J., Qiu S.J., Li Y., Ji X.N., Liu H., Xia J.L., Wu Z.Q., Fan J., Ma Z.C., Zhou X.D., Lin Z.Y., Liu K.D. A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130:187-196.
4. Yang Y., Nagano H., Ota H., Morimoto O., Nakamura M., Wada H., Noda T., Damdinsuren B., Marubashi S., Miyamoto A., Takeda Y., Dono K., Umeshita K., Nakamori S., Wakasa K., Sakon M., Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007, 141:196-202.
5. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., Simon R., Li Y., Robles A.I., Chen Y., Chen Y., Ma Z.C., Wu Z.Q., Ye S.L., Liu Y.K., Tang Z.Y., Wang X.W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 2003, 9:416-423.
6. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., Xu Y., Li Y.W., Tang Z.Y. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007, 25:2586-2593.
7. Yang X.R., Xu Y., Shi G.M., Fan J., Zhou J., Ji Y., Sun H.C., Qiu S.J., Yu B., Gao Q., He Y.Z., Qin W.Z., Chen R.X., Yang G.H., Wu B., Lu Q., Wu Z.Q., Tang Z.Y. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin. Cancer Res. 2008, 14:3850-3859.
8. Peng S.Y., Chen W.J., Lai P.L., Jeng Y.M., Sheu J.C., Hsu H.C. High a-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53, and β-catenin mutations. Int. J. Cancer 2004, 112:44-50.
9. Qin L.X., Tang Z.Y. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J. Cancer Res. Clin. Oncol. 2004, 130:497-513.
10. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
11. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
12. Finley D., Ciechanover A., Varshavsky A. Ubiquitin as a central cellular regulator. Cell 2004, 116:S29-S32. (2-32).
13. Sridhar V.V., Kapoor A., Zhang K., Zhu J., Zhou T., Hasegawa P.M., Bressan R.A., Zhu J.K. Control of DNA methylation and heterochromatic silencing by histone H2B deubiquitination. Nature 2007, 447:735-738.
14. Liu H., Buus R., Clague M.J., Urbe S. Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PLoS One 2009, 4:e5544.
15. Singhal S., Taylor M.C., Baker R.T. Deubiquitylating enzymes and disease. BMC Biochem. 2008, 9(Suppl. 1):S3.
16. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry-Us 1998, 37:3358-3368.
17. Yao T., Song L., Xu W., DeMartino G.N., Florens L., Swanson S.K., Washburn M.P., Conaway R.C., Conaway J.W., Cohen R.E. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat. Cell Biol. 2006, 8:994-1002.
18. Schreiner P., Chen X., Husnjak K., Randles L., Zhang N., Elsasser S., Finley D., Dikic I., Walters K.J., Groll M. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 2008, 453:548-552.
19. Husnjak K., Elsasser S., Zhang N., Chen X., Randles L., Shi Y., Hofmann K., Walters K.J., Finley D., Dikic I. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008, 453:481-488.
20. Yao T., Song L., Jin J., Cai Y., Takahashi H., Swanson S.K., Washburn M.P., Florens L., Conaway R.C., Cohen R.E., Conaway J.W. Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex. Mol. Cell 2008, 31:909-917.
21. Zediak V.P., Berger S.L. Hit and run: transient deubiquitylase activity in a chromatin-remodeling complex. Mol. Cell 2008, 31:773-774.
22. Fang Y., Fu D., Shen X.Z. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim. Biophys. Acta 2010, 1806:1-6.
23. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
24. Kanehisa M., Goto S., Kawashima S., Okuno Y., Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004, 32:D277-D280.
25. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007, CA. Cancer J. Clin. 2007, 57:43-66.
26. Amerik A.Y., Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta 2004, 1695:189-207.
27. Soboleva T.A., Baker R.T. Deubiquitinating enzymes: their functions and substrate specificity. Curr. Protein Pept. Sci. 2004, 5:191-200.
28. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
29. Rolen U., Kobzeva V., Gasparjan N., Ovaa H., Winberg G., Kisseljov F., Masucci M.G. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol. Carcinog. 2006, 45:260-269.
30. Kapuria V., Peterson L.F., Fang D., Bornmann W.G., Talpaz M., Donato N.J. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010, 70:9265-9276.
31. Chen Y., Fu D., Xi J., Ji Z., Liu T., Ma Y., Zhao Y., Dong L., Wang Q., Shen X. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig. Dis. Sci. 2012, 57:2310-2317.
32. Wicks S.J., Haros K., Maillard M., Song L., Cohen R.E., Dijke P.T., Chantry A. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signaling. Oncogene 2005, 24:8080-8084.
33. Wicks S.J., Grocott T., Haros K., Maillard M., Ten D.P., Chantry A. Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. Biochem. Soc. Trans. 2006, 34:761-763.
34. Cutts A.J., Soond S.M., Powell S., Chantry A. Early phase TGFβ receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses. Int. Biochem. Cell Biol. 2011, 43:604-612.
35. Chen Z., Niu X., Li Z., Yu Y., Ye X., Lu S., Chen Z. Effect of ubiquitin carboxy-terminal hydrolase 37 on apoptotic in A549 cells. Cell Biochem. Funct. 2011, 29:142-148.
36. Fang Y., Mu J., Ma Y., Ma D., Fu D., Shen X. The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma. Mol. Cell. Biochem. 2012, 359:59-66.
37. Boehm A.M., Putz S., Altenhofer D., Sickmann A., Falk M. Precise protein quantification based on peptide quantification using iTRAQ. BMC Bioinformatics 2007, 8:214.
38. Gan C.S., Chong P.K., Pham T.K., Wright P.C. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J. Proteome Res. 2007, 6:821-827.
39. Wiese S., Reidegeld K.A., Meyer H.E., Warscheid B. Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7:340-350.
40. Han C.L., Chien C.W., Chen W.C., Chen Y.R., Wu C.P., Li H., Chen Y.J. A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease. Mol. Cell. Proteomics 2008, 7:1983-1997.
41. Ralhan R., Desouza L.V., Matta A., Chandra T.S., Ghanny S., Datta G.S., Bahadur S., Siu K.W. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol. Cell. Proteomics 2008, 7:1162-1173.
42. Sutton C.W., Rustogi N., Gurkan C., Scally A., Loizidou M.A., Hadjisavvas A., Kyriacou K. Quantitative proteomic profiling of matched normal and tumor breast tissues. J. Proteome Res. 2010, 9:3891-3902.
43. Goh W.W., Lee Y.H., Zubaidah R.M., Jin J., Dong D., Lin Q., Chung M.C., Wong L. Network-based pipeline for analyzing MS data: an application toward liver cancer. J. Proteome Res. 2011, 10:2261-2272.
44. Chiu K.H., Chang Y.H., Wu Y.S., Lee S.H., Liao P.C. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J. Proteome Res. 2011, 10:1110-1125.
45. Chan S.P., Kao D.I., Tsai W.Y., Cheng S.C. The Prp19p-associated complex in spliceosome activation. Science 2003, 302:279-282.
46. Makarova O.V., Makarov E.M., Urlaub H., Will C.L., Gentzel M., Wilm M., Luhrmann R. A subset of human 35S U5 proteins, including Prp19, function prior to catalytic step 1 of splicing. EMBO J. 2004, 23:2381-2391.
47. Chan S.P., Cheng S.C. The Prp19-associated complex is required for specifying interactions of U5 and U6 with pre-mRNA during spliceosome activation. J. Biol. Chem. 2005, 280:31190-31199.
48. Valadkhan S., Jaladat Y. The spliceosomal proteome: at the heart of the largest cellular ribonucleoprotein machine. Proteomics 2010, 10:4128-4141.
49. Chanarat S., Seizl M., Straber K. The Prp19 complex is a novel transcription elongation factor required for TREX occupancy at transcribed genes. Genes Dev. 2011, 25:1147-1158.
50. David C.J., Boyne A.R., Millhouse S.R., Manley J.L. The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex. Genes Dev. 2011, 25:972-983.
51. Cooper T.A., Wan L., Dreyfuss G. RNA and disease. Cell 2009, 136:777-793.
52. Confalonieri S., Quarto M., Goisis G., Nuciforo P., Donzelli M., Jodice G., Pelosi G., Viale G., Pece S., Di Fiore P.P. Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene 2009, 28:2959-2968.
53. Lu X., Legerski R.J. The Prp19/Pso4 core complex undergoes ubiquitylation and structural alterations in response to DNA damage. Biochem. Biophys. Res. Commun. 2007, 354:968-974.
54. Zhang N., Kaur R., Lu X., Shen X., Li L., Legerski R.J. The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J. Biol. Chem. 2005, 280:40559-40567.
55. Mahajan K.N., Mitchell B.S. Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10746-10751.
56. Voglauer R., Chang M.W., Dampier B., Wieser M., Baumann K., Sterovsky T., Schreiber M., Katinger H., Grillari J. SNEV overexpression extends the life span of human endothelial cells. Exp. Cell Res. 2006, 312:746-759.
57. Legerski R.J. The Pso4 complex splices into the DNA damage response. Cell Cycle 2009, 8:3448-3449.